BIBW 2992

BIBW 2992

File:BIBW 2992 structure.svg
Systematic (IUPAC) name
N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3''S'')-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide
Clinical data
Routes of administration	Oral
Identifiers
CAS Number	439081-18-2
ATC code	none
PubChem	CID 10184653
ChemSpider	8360155
Chemical data
Formula	C24H25ClFN5O3
Molar mass	485.937 g/mol[[]]

BIBW 2992 (planned trade name Tovok) is a candidate drug against non-small cell lung carcinoma, developed by Boehringer Ingelheim. As of December 2008, it is undergoing a Phase III clinical trial for this indication, and Phase II trials for breast, prostate, and head and neck cancers, as well as glioma.

Mechanism of action

Like lapatinib and neratinib, BIBW 2992 is a next generation tyrosine kinase inhibitor (TKI) that irreversibly inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases. BIBW-2992 is not only active against EGFR mutations targeted by first generation TKIs like erlotinib or gefitinib, but also against those not sensitive to these standard therapies. Because of its additional activity against Her2, it is investigated for breast cancer as well as other EGFR and Her2 driven cancers.